This year in Marbella we will have three Social Events.
People wanting to buy tickets for their guests will be able to do so from the FMF reception.

Welcome reception

• Sunday 23rd June 2013

• Time: 20:30 - 22:00

The welcome reception will take place at the plaza del' Inglesia which is at the old town of Marbella. It is a 15-20 minute walk from the Congress Centre for those who want to take short promenade, otherwise there will be buses outside to take you to the old town.
We will have plenty of drinks including sangria and various canapes.
At around 21:30 we will have a flamenco company performing for you.
After the reception those of you who want to eat there are plenty of restaurants around or you can simply explore the old town of Marbella.

Dinner party

• Tuesday 25th June 2013

• Time: 21:00-02:45

The dinner party is going to take place at the Bull Arena of Marbella.
There will be buses leaving from outside the Marbella Congress from 20:30-21:30 to take all the delegates there.
At 12:00 the first bus will be leaving from there to take you back.
Each bus will be leaving once it is full.
The last bus will leave from the bull arena at 02:45.
People missing the last bus will need to find their own way back to their hotels.

Trip to Ronda

• Thursday 27th June 2013
• Time: 16:00-24:00

This year the trip is going to be to the beautiful and picturesque city of Ronda.
Buses will be leaving from outside the Congress Centre at 16:00 and then departing from Ronda at 23:30.

• World Congress main page

• Abstracts

• Airport transfers

• Accommodation

• Visas

• Registration

• Sponsors and Exhibitors

Quicklinks

• Introduction
• Preterm preeclampsia
• Low-dose aspirin in early pregnancy
• Proposed study

• Initiation of low-dose aspirin in early pregnancy

In most studies that evaluated aspirin for the prevention of PE the onset of treatment was after 16 weeks' gestation. However, examination of a small number of randomised trials of low-dose aspirin in women at high-risk for PE suggests that the effectiveness of therapy is related to the gestational age at the onset of treatment. A meta-analysis by Bujold et al. (2010) reported that low-dose aspirin started at 16 weeks or earlier was associated with a significant reduction in the relative risk (RR) for PE (0.47, 95% confidence interval [CI] 0.34 - 0.65) and fetal growth restriction (FGR) (0.44, 95% CI 0.30 - 0.65; Bujold et al., 2010). In contrast, aspirin started after 16 weeks did not have a significant benefit (PE: RR 0.81, 95% CI: 0.63-1.03; FGR: RR 0.98, 95% CI: 0.87-1.10). More detailed analysis of the data on PE demonstrated that low-dose aspirin started at or before 16 weeks' gestation was particularly effective in preventing preterm-PE rather than term-PE (RR: 0.11, 95% CI: 0.04-0.33 vs. RR: 0.98, 95% CI: 0.42-2.33; Roberge et al., 2012).
However, the small number and small size of individual trials preclude definitive conclusions to be drawn regarding the effectiveness of aspirin starting before 16 weeks and the results need to be examined in a prospective major randomised trial.

• Aspirin resistance

Low-dose aspirin is defined as less than 300 mg per day. There is evidence that approximately 30%, 10% and 5% of pregnant women are "aspirin resistant" with dosage of 81 mg, 121 mg, and 162 mg, respectively (Caron et al., 2009). Furthermore, a retrospective cohort study reported that women who were identified by the PFA-100 test as being resistant to 81 mg of aspirin were less likely to develop severe PE when the dose of aspirin was increased from 81 to 162 mg, compared to those who continued with 80 mg (Rey and Rivard, 2011). Consequently, a trial investigating the effectiveness of low-dose aspirin in the prevention of preterm-PE should use a dose closer to 160 mg rather than 80 mg.

• Safety of low-dose aspirin

The relative safety of first-trimester use of low-dose aspirin has been demonstrated in large cohort and case-control studies which reported that the drug is not associated with increase in risk of congenital heart defects or other structural or developmental anomalies (Slone et al., 1976; Klebanoff and Berendes, 1988; Werler et al., 1989; Norgard et al., 2005).
Potential risks associated with aspirin therapy during the third-trimester include haemorrhagic complications to the mother or fetus and premature closure of the ductus arteriosus for the fetus.
Randomised studies reported that although approximately 10% of women receiving low-dose aspirin complained of gastro-intestinal symptoms there was no evidence of increase in any type of maternal bleeding (Sibai et al., 1993; Caritis et al., 1998; Rotchell et al., 1998). Similarly, the best evidence suggests that low-dose aspirin started before 16 weeks' gestation does not increase the risk of placental abruption (RR: 0.62, 95% CI: 0.08-5.03; Bujold et al., 2010). No additional adverse effects related to epidural anesthesia have been reported in women taking low-dose aspirin compared to those taking placebo (Sibai et al., 1995).
Prospective and case-control studies did not find an association between daily consumption of 60-150 mg of aspirin during the third-trimester and antenatal closure of the ductus arteriosus (Di Sessa et al., 1994; Schiessl et al., 2005; Wyatt-Ashmead, 2011). A meta-analysis including more than 26,000 women randomised to low-dose (80-150 mg) aspirin or placebo/no treatment during pregnancy demonstrated that the use of aspirin was not associated with an increase in intra-ventricular hemorrhage or other neonatal bleeding (Duley et al., 2007).
In the trials evaluating the effect of aspirin for the prevention of PE in high-risk women, treatment was continued until a pre-specified gestation between 34 and 37 weeks or until delivery. On the basis of currently available evidence it would be reasonable to continue with low-dose aspirin well into the third-trimester of pregnancy.

Quicklinks

• Introduction
• Preterm pre-eclampsia
• Proposed study
• Sponsors and partners

The trial will be conducted in compliance with the protocol, the Declaration of Helsinki (1996), the principles of Good Clinical Practice (GCP) and applicable regulatory requirements. The study will be reviewed and approved by the National Research Ethics Committee (NREC), Medicine and Healthcare products Regulatory Agency (MHRA) and applicable Hospital Trusts. The Joint Clinical Trials Office of King's Health Partners will manage the sponsors' responsibilities and Quality Assurance to ensure compliance with the Clinical Trial Regulations.
This will be a multicentre trial in the UK and other countries in the European Union. In all the participating centres, all women attending for their routine first hospital visit in pregnancy at 11-13 weeks' gestation are offered combined screening for aneuploidies by measurement of the fetal crown-rump length (CRL) and nuchal translucency (NT) thickness and maternal serum PAPP-A, free ß-hCG and PlGF (Robinson and Fleming 1975; Snijders et al., 1998; Kagan et al., 2008, Pandya et al., 2012). In women who agree to participate in the study, after obtaining informed consent we also measure the maternal MAP by automated devices (Poon et al., 2012), use transabdominal colour Doppler ultrasound to visualise the left and right uterine artery and measure the PI in each vessel and calculate the mean PI (Plasencia et al., 2007). The principal investigators for each site are doctors who received their training at Kings' college hospital and follow the Fetal Medicine Foundation guidelines on how to undertake the appropriate measurements.
The psychological impact of screening for PE and participation in the aspirin vs. placebo trial will be examined. Specifically, we aim to establish whether providing information regarding one's risk for PE, which is associated with significant maternal and fetal adverse outcomes, will lead to any short and medium term adverse psychological effects. Specific psychological outcomes that will be examined include anxiety, depression, worry and perceptions of own health and of the unborn child, health status, and health behaviours, at various points during pregnancy. Additionally, using the Coping Orientation to Problems Experienced Scale (COPE; Carver et al., 1989) and the Metacognitions Questionnaire (MCQ-30, Wells & Cartwright-Hutton, 2004), the role of illness representations and cognitions and women's coping strategies in relation to the threat posed by being identified as high-risk for PE will be examined.
Women who are deemed to be at high-risk for preterm-PE (about 10% of the population) will be offered the opportunity to participate in the aspirin vs. placebo trial. They will receive an information leaflet outlining the objectives of the study and those providing informed consent will receive counselling regarding the implications of this finding and will be offered the option of participating in a randomised study of aspirin versus placebo. Counselling will be undertaken by the research co-ordinator in each hospital and women can opt to participate after consideration on the same day or after 24 hours, written consent will be obtained.
All women undergoing screening for PE will also be invited to participate in the study to evaluate the psychological impact of screening. Those providing informed consent will be asked to complete series of questionnaires at specific points during pregnancy.
A small subsection of women (n=80) will also be interviewed using semi-structured interviews to examine their beliefs concerning their risk status and of partaking in the trial. Such in-depth exploration of women's perceptions of the impact of screening, and of partaking in the trial will enable greater understanding and a richer account of women's experiences than that which can be achieved solely through the quantitative methodology. The interviews, which will also explore women's cognitions and representations of PE and will be theoretically nested within the Common-Sense Model of illness (Lau and Hartman, 1983; Leventhal et al., 1992). These semi-structured interviews will be conducted in women's homes or at the participating hospitals between 20-24 and 30-32 weeks of pregnancy, in the King's College Hospital sample only.

Quicklinks

• Introduction
• Preterm pre-eclampsia
• Low-dose aspirin in early pregnancy
• Sponsors and partners

Extensive research in the last 20 years, mainly as a consequence of the shift in screening for aneuploidies from the second to the first-trimester of pregnancy, has identified a series of early biophysical and biochemical markers of impaired placentation (Akolekar et al., 2011). A combination of maternal demographic characteristics, including medical and obstetric history, uterine artery pulsatility index (PI), mean arterial pressure (MAP) and maternal serum pregnancy associated plasma protein-A (PAPP-A) and placental growth factor (PlGF) at 11-13 weeks' gestation can identify a high proportion of pregnancies at high-risk for PE (Akolekar et al., 2011). A recent study involving more than 60,000 singleton pregnancies examined at 11-13 weeks' gestation has further refined the prediction algorithm for PE. Using this algorithm the estimated detection rate of preterm-PE was 76%, at a false positive rate of 10% (Akolekar et al., 2012). Consequently, there is a well described approach for effective screening for preterm-PE at the time of routine screening for aneuploidies at 11-13 weeks' gestation.

• Prevention of preterm pre-eclampsia

The prophylactic use of low-dose aspirin for prevention of PE has been an important research question in obstetrics for the last three decades. In 1979, Crandon and Isherwood observed that nulliparous women who had taken aspirin regularly during pregnancy were less likely to have PE than women who did not. Subsequently, more than 50 trials have been carried out throughout the world and a meta-analysis of these studies reported that the administration of low-dose aspirin in high-risk pregnancies is associated with a decrease in the rate of PE by approximately 10% (Askie et al., 2007).

• Psychological effects of screening for pre-eclampsia

Many studies have examined the impact of antenatal screening for conditions that affect the fetus, such as Down syndrome, however, there are only few studies which have examined the psychological impact of screening for conditions that affect maternal health (Harris et al., 2013). Harris et al. (2013) have recently conducted a systematic review of studies examining various cognitive, emotional and behavioural effects of screening for gestational diabetes (3 studies) and HIV (15 studies) in pregnant women. Due to methodological limitations of the studies (i.e. cross-sectional designs and the use of non-validated measures of psychological outcomes), the authors have concluded that it remains unclear whether prenatal screening for conditions that affect maternal health leads to an increase in women's distress following a screen-positive result, with some studies suggesting no impact on emotions and others indicating an increase in anxiety and worry. Similarly, it is unclear whether screening affects women's health behaviours (i.e. brings about changes in women's health habits) and affects their quality of life.
The concerns associated with the introduction of novel screening tests that affect women's health include whether being identified as screen-positive will increase women's distress in terms of elevations in anxiety, worry about the health of the baby and her own health, impact on mood and reduced quality of life generally. On the other hand, there could also be potential benefits; apart from the reassurance provided to those who are identified as low-risk and the possibility of successful treatment in those identified as high-risk, there could also be additional benefits for the mother, and her unborn child, in terms of positive changes in maternal health behaviours, such as reduced sugar, salt and alcohol intake and increase in physical activity.
Introduction of novel screening tests is endorsed in the UK if the benefits outweigh any physical and psychological harm (UK National Screening Committee; Gray, 1998). It is therefore important to establish the psychological impact of our proposed screening for PE in order to provide support to those who are identified as high-risk.

Quicklinks

• Introduction
• Low-dose aspirin in early pregnancy
• Proposed study
• Sponsors and partners

Project "ASPRE": Combined Multi-Marker Screening and Randomised Patient Treatment with Aspirin for Evidence-Based Pre-eclampsia Prevention

Coordinator: Prof. Kypros Nicolaides

Pre-eclampsia (PE) is an important cause of maternal and perinatal mortality and morbidity. There is extensive evidence that the risk of adverse outcome in relation to PE is much higher when the disease is severe and of early onset requiring delivery before 37 weeks' gestation (preterm-PE) than at term (Witlin et al., 2000; Irgens et al., 2001; von Dadelszen et al., 2003; Yu et al., 2008). A major challenge in modern obstetrics is early identification of pregnancies at high-risk of preterm-PE and undertaking of the necessary measures to improve placentation and reduce the prevalence of the disease.

• Preterm preeclampsia

• Low-dose aspirin in early pregnancy

• Proposed study

• Sponsors and partners

Trial Identifiers

• FP7-HEALTH-2013-INNOVATION-2
• EudraCT Number: 2010-023659-26
• ISRCTN: ISRCTN13633058
• WHO UTN: U1111-1140-4837

• Samsung (Platinum)
• Perkin Elmer (Gold)
• Ariosa Diagnostics (Silver)
• Roche (Silver)
• Natera (Silver)
• ThermoFisher (Bronze)
• Sequenom (Standard Plus)
• Astraia (Standard)
• Hitachi - Aloka (Standard)
• LifeCodexx (Standard)
• Toshiba (Standard)
• Karl Storz (Standard)

SPONSORS PROFILES:

PLATINUM SPONSOR

Samsung.

http://www.samsung.com/global/business/healthcare/

Samsung has contributed to the digital revolution through products that encompass innovative technologies, original designs,
convenience, and customer values, and has always been a leader of such revolution. By branching out into the medical equipment industry, Samsung
aims to become a global leader as a healthcare company through joining together its IT, image processing, semiconductor and
communication technologies into medical devices. The Health and Medical Equipment Business now sells cutting-edge medical devices including
diagnostic ultrasound, digital X-ray, blood analyzer and CT scanner in more than 110 countries around the world.

For more information please visit our website:
http://www.samsung.com/global/business/healthcare/

GOLD SPONSOR

PerkinElmer.
www.perkinelmer.com/MaternalFetalHealth

PerkinElmer is a global company focused on improving the health and safety of people and their environment.
Targeting health right at the start of life, the company supplies a range of instruments and serum-based or dried blood spot-based assays for 1st and 2nd trimester aneuploidy screening.
For faster and more comprehensive prenatal diagnosis Prenatal BoBs™ is a bead-based multiplex assay designed to detect aneuploidies of chromosomes 13, 18, 21, X and Y, as well as copy number changes in 9 common microdeletion syndrome regions.
PerkinElmer has also the world's first PlGF assay intended for 1st trimester prediction of pre-eclampsia.

For more information, please visit www.perkinelmer.com

SILVER SPONSORS

Ariosa Diagnostics.
www.ariosadx.com

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif.

For more information, visit www.ariosadx.com.
Follow us on Twitter @HarmonyPrenatal, and on Facebook at Harmony Prenatal for Healthy Pregnancy.

Roche.
www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com

Natera.
www.natera.com

In late 2012 Natera announced The PanoramaTM Test, the most accurate and comprehensive non-invasive prenatal test available. Natera has a history of proven excellence in reproductive genetic testing having previously launched preimplantation genetic diagnosis (PGD) for IVF, carrier screening and the only prenatal non-invasive paternity test.

Web links:
Panorama Test
Natera

BRONZE SPONSOR

ThermoFisher Scientific.
www.thermoscientific.com

Thermo Scientific B•R•A•H•M•S Biomarkers investigates, develops and manufactures novel diagnostic testing procedures to improve early diagnosis and treatment of life threatening diseases. With high-quality immunodiagnostic tests for sepsis, cardiovascular, pulmonary, and cancer disorders as well as prenatal screening we contribute to the creation of a healthier future - to the greatest advantage for medical professionals and patients.
In future simple and economic blood tests will be of great importance for an early detection and successful treatment of diseases. With our know-how and technologies we are confident to play an active role in this future: Our products provide important information to clinicians and laboratories in more than 130 countries worldwide, supporting their clinically and economically relevant decisions.
The Gold Standard in Prenatal Screening on KRYPTOR Systems is expanded by a PlGF assay to allow an early screening for preeclampsia already in first trimester
Screening for preeclamspia with the B•R•A•H•M•S PlGF KRYPTOR test enables an early risk assessment of pregnant women already during the first trimester of pregnancy. It helps to identify women at risk earlier and, therefore provides optimal patient care. This latest addition of the PlGF assay is a highly valuable complement to Thermo Fisher's already existing Prenatal Screening portfolio (PAPP-A, Free βhCG, AFP, hCG+β, Fast Screen pre I plus software). Ongoing research and development activities in that field will further support the product range in PNS.
All B•R•A•H•M•S KRYPTOR platforms are FMF approved and in routine use since 1999, providing reliable results and meeting the highest quality standards of FMF.

STANDARD PLUS SPONSOR

Sequenom Centre for Molecular Medicine.
www.SequenomCMM.com

Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. Branded under the names MaterniT21™ PLUS, Heredi-T™, SensiGene®, and RetnaGene™, these molecular genetic laboratory tests provide early patient management information for obstetricians, geneticists, maternal fetal medicine specialists, retina specialists and ophthalmologists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

STANDARD SPONSOR

Astraia.
https://www.astraia.com/en/

Astraia software is based in Munich, Germany and was founded in 2000.
Astraia has established its position as a market leader and pioneer in obstetric and gynaecological database application. Today a dedicated team is taking care of more than 1,000 customers worldwide and is also represented by local sales partners. astraia is known for offering high end solutions, always up-to-date with the latest scientific data.
The company's success is due to a close working relationship with leading experts, a successful co-operation with FMF London, in-house expertise and highly flexible adaptation to market requirements. The core product is Astraia software for women's health.

Hitachi - Aloka.
www.hitachi-medical-systems.com

Hitachi Medical Systems Europe offer their extensive experience in ultrasound imaging with the HI VISION and ProSound ultrasound range providing the clinician with imaging solutions that cover not only multipurpose ultrasound applications, but also powerful high-field MR, multi-slice CT and optical topography systems. We always focus on superior image quality, in combination with image optimization features, and cutting edge technology such as Auto NT Measurements, to provide diagnostic ultrasound imaging confidence in the field of Women´s Healthcare. Our many years' experience allows us to offer a wide range of products in order to meet the needs of customers in Obstetrical & Gynecological practice. We can provide an optimum solution for every department, practice, and for every diagnostic requirement.
During the 12th FMF Congress, you will see new tools that help to identify major risk indicators during the 1st trimester of the pregnancy with our premium systems for Obstetrics & Gynecology.

LifeCodexx.
www.lifecodexx.com

LifeCodexx AG is a German life science company focusing on the development of clinically validated molecular diagnostic tests based on the use of next generation sequencing techniques - focused on prenatal diagnostics.
The non-invasive molecular genetic PrenaTest® is able to detect fetal trisomies 21, 18 and 13 with a high degree of accuracy from maternal blood. With its low false positive rate of 0.2% it further clarifies early diagnosis of fetal malformation and therefore reduces the number of unnecessary invasive examinations of non-affected pregnancies. Thus, PrenaTest® complements common prenatal examinations and does not carry the risk of procedure-related fetal losses.

Toshiba Medical Systems.
www.toshiba-medical.eu

For over 130 years Toshiba's research and development has improved the health and welfare of people around the world.
Today, Toshiba Medical Systems offers a full range of diagnostic imaging products and is a reliable service partner in more than 110 countries.
In accordance with our Made for Life™ commitment, we will continue to develop innovations that improve patient care and provide lasting quality for a lifetime of value.

Karl Storz.
www.karlstorz.com

KARL STORZ is a renowned manufacturer that is well established in all fields of endoscopy and can be considered as market leader in rigid endoscopy. The still family held company was founded in 1945 in Tuttlingen, Germany, and has grown to one with a worldwide presence and 5800 employees.
KARL STORZ offers a range of both rigid and flexible endoscopes for a broad variety of applications. Today's product range also includes fully integrated concepts for the OR and servicing.

• World Congress main page

• Abstracts

• Airport transfers

• Accommodation

• Visas

• Registration

The registration fee for the 12th FMF World Congress is 400€ (Eurofetus meeting included) The registration fee only for the Eurofetus meeting (23 and 24 June) is 250€.

Registration can be done in the following ways:

• Online: before completing the online form please note:

1. Use only English characters ( ü ä ö ß í é ę ç ğ etc. will only appear on our database as a question mark (?) and hence your names will be unreadable).
2. Make sure you put your first name and surname where appropriate.
3. Please avoid putting your title (Dr, MD, etc.) in front of your name.

Failure to complete your online registration correctly will result in getting your badges, receipts and certificates printed with mistakes so please double check everything before clicking "Register".

To register online please click here
Please note that there is an extra charge of 10€ per registration when using a credit card to make the online payment.

• By Bank Transfer:

Please contact Kristis at kristis@fetalmedicine.com in order to provide you with the bank transfer form. Once you make the payment, you must return it completed via email together with the receipt you get from the bank when you make the deposit.
Please do not use this method of payment after the 10th of June 2013.

Registration Cancellation

Notification of cancellation should be send by email to kristis@fetalmedicine.com

• Cancellations up until the 30th of May 2013 will be fully refunded.
• Cancellations from the 1st up to and including the 15th of June will be refunded minus a 25% cancellation charge.
• No refunds will be made for cancellations after the 15th of June unless under exceptional circumstances, something that will be at the sole discretion of the Organising Committee.

• World Congress main page

• Abstracts

• Accommodation

• Airport transfers

• Visas

• Sponsors and Exhibitors

Please note: Spellcheck and proofread your entries before submitting them, and also make sure that you use only English characters (ü ä ö ß í é ę ç ğ etc. will only make your names or words unreadable). The Fetal Medicine Foundation will not be responsible for any spelling mistakes, inaccuracies or other errors due to incorrect input on your part.

Please make sure that you complete all requested fields in the form. In the section of "Abstract author(s)" please write down the Initials in Capital Letters and only the Surname of each author.

The abstract should be structured using the following headings:

• For original work: Objective, Methods, Results, Conclusions
• For case reports: No headings

The submitted Abstracts will be assessed by Professor Nicolaides and the Scientific Committee. The contact person will be notified by an email whether the Abstract is accepted or not. If successful, we will let you know whether it is accepted for an oral or poster presentation and give you guidelines for either case.

To submit an Abstract please click here

• World Congress main page

• Accommodation

• Airport transfers

• Visas

• Registration

• Sponsors and Exhibitors

1. Name as it appears on the passport
2. Date of birth
3. Passport number
4. Address where you want to have the letter posted.

Please also note

• People accompanied by their families please send the same (1-3) for the people coming with you so as to be included in the letter.
• There are Embassies that will accept the letter from the FMF and others that will need a letter from our representative in Spain. Please check it out and state in your email exactly what the Spanish Embassy in your country needs.
• Requests for Visa letter after the 20th of May will only be sent to you via email or fax.
• Please arrange your appointments for visa well in advance.

return to congress main page

• World Congress main page

• Abstracts

• Accommodation

• Airport transfers

• Registration

• Sponsors and Exhibitors

FMF trying to help the attendees and get cheap prices, is cooperating with "Viajes El Corte Ingles" and has managed to get the following prices which will remain fixed during the FMF Congress. These prices are for a single transfer from Malaga International Airport to Marbella or from Marbella to Malaga International Airport.

If you want to book for one of the above services you can do it:

• Online, by clicking here ^new
• or via this form, which after completed please email to fmf2013@viajeseci.es

return to congress main page

• World Congress main page

• Abstracts

• Accommodation

• Visas

• Registration

• Sponsors and Exhibitors

• אבחון מוקדם של מומים בעובר
• הקרנת עבור פגם כרומוזומלי
• ניתוח עוברי תוך רחמי
• גורם ומניעת להפלות וללידת עובר מת
• חיזוי ומניעת לידה מוקדמת
• רעלת הריון והגבלת הגידול העוברי
• בעיות של הריונות מרובים
• פיתוח שיטות בטוחות יותר לאבחון טרום לידתי
  

אם אתה איש מקצוע בריאות אתה רוצה ללכת לדף FMF משלך עליך להכנס להלן:

הקורסים הם ללא תשלום והם מתאימים גם אנשי מקצוע בתחום הבריאות והחולים

בשבועות 11-13 סריקה
הערכה צוואר הרחם
מעקב ההיריון
עוברית אקו

• To book your desired hotel online please click here
• The rooms will be available until 23rd of May 2013 and the fully booked hotels will be deducted from the list.
• For a list of Hotels and prices together with the option for a shuttle service, please click here
• If you prefer not to pay online for your accommodation and/or shuttle service, you can do it by Bank Transfer via this form which after completing please send it together with the receipt you will get from the bank to fmf2013@viajeseci.es

If you decide to ask for a shuttle service after you have booked your hotel, at a later point, you can do it via the above links by filling in the "shuttle service" section .

return to congress main page

• World Congress main page

• Abstracts

• Airport transfers

• Visas

• Registration

• Sponsors and Exhibitors